Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists

Diabetes/metabolism Research and Reviews
Francesco GiorginoPaolo Pozzilli

Abstract

A substantial proportion of patients with type 2 diabetes mellitus do not reach glycemic targets, despite treatment with oral anti-diabetic drugs and basal insulin therapy. Several options exist for treatment intensification beyond basal insulin, and the treatment paradigm is complex. In this review, the options for treatment intensification will be explored, focusing on drug classes that act via the incretin system and paying particular attention to the short-acting glucagon-like peptide-1 receptor agonists exenatide and lixisenatide. Current treatment guidelines will be summarized and discussed. © 2016 The Authors. Diabetes/Metabolism Research and Reviews Published by John Wiley & Sons Ltd.

References

Jun 19, 2001·American Journal of Physiology. Endocrinology and Metabolism·C M EdwardsS R Bloom
May 27, 2003·Diabetes Care·Philip E CryerHarry Shamoon
Aug 25, 2006·Nature Clinical Practice. Endocrinology & Metabolism·Daniel J Drucker
Feb 23, 2007·Diabetes/metabolism Research and Reviews·Denis RaccahMatthew Riddle
Jul 12, 2007·JAMA : the Journal of the American Medical Association·Renee E AmoriAnastassios G Pittas
Oct 11, 2007·Diabetes, Obesity & Metabolism·David Russell-Jones, Rehman Khan
Jan 29, 2008·Pediatric Diabetes·Rebecca J Brown, Kristina I Rother
Jun 4, 2008·Diabetes, Obesity & Metabolism·J C N ChanD Williams-Herman
Sep 25, 2008·The Journal of Clinical Endocrinology and Metabolism·Jessica E MatthewsUNKNOWN Albiglutide Study Group
Aug 14, 2009·The Journal of Physiology·Gregory M HolmesR Alberto Travagli
Nov 13, 2009·Diabetes Care·Simona CerneaPaolo Pozzilli
May 21, 2010·Diabetes Care·Diana SherifaliHertzel C Gerstein
Dec 21, 2010·Cardiovascular Therapeutics·Theodore Okerson, Robert J Chilton
Feb 18, 2011·Current Medical Research and Opinion·Jean DoucetJulio Rosenstock
Mar 17, 2011·Advances in Clinical Chemistry·Kei OhnumaChikao Morimoto
Nov 22, 2011·Diabetes, Obesity & Metabolism·Katherine R GerraldD E Jonas
Dec 1, 2011·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Timothy Colin Hardman, Simon William Dubrey
Feb 11, 2012·Endocrine Reviews·John R Ussher, Daniel J Drucker

❮ Previous
Next ❯

Citations

May 2, 2018·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Michal WitkowskiHrvoje Vrazic
Feb 2, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Penelope J TaylorGrant D Brinkworth
Aug 25, 2017·Current Medical Research and Opinion·Ronald M Goldenberg, Lori Berard
Mar 17, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Barrie ChubbMichelle Orme
May 18, 2021·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Angelo AvogaroFrancesco Purrello

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01147250
NCT01144338
NCT01179048
NCT01394952

Software Mentioned

GetGoal
Duo2

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Related Papers

Giornale italiano di cardiologia : organo ufficiale della Federazione italiana di cardiologia : organo ufficiale della Società italiana di chirurgia cardiaca
Edoardo Mannucci
Giornale italiano di cardiologia : organo ufficiale della Federazione italiana di cardiologia : organo ufficiale della Società italiana di chirurgia cardiaca
Gian Franco Gensini
Expert Opinion on Investigational Drugs
Mikkel ChristensenJens J Holst
© 2022 Meta ULC. All rights reserved